The amount of funding received by UK life science companies reached a 10-year high last year, indicating Britain is finally starting to catch up with the US in biotech.
According to a report by the UK Bioindustry Association, $2.4bn (£1.7bn) was pumped into sector through venture capital over the 10 year period, while £923.7m was raised through flotations.
In 2014 alone, biotech IPOs brought the UK £408m – an eightfold increase from the year before. Investment, meanwhile, rose 71 per cent.
